FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386748890> ?p ?o ?g. }

• W4386748890 endingPage "2318" @default.
• W4386748890 startingPage "2318" @default.
• W4386748890 abstract "Tacrolimus (TAC) and mycophenolic acid (MPA) are commonly used immunosuppressive therapies after renal transplant. Our objective was to quantify TAC and MPA concentrations in peripheral blood mononuclear cells (PBMCs) using liquid chromatography tandem mass spectrometry (LC-MS/MS) and to evaluate and validate the performance of the methodology. A prospective follow-up cohort study was conducted to determine whether intracellular concentrations were associated with adverse outcomes in renal transplants.PBMCs were prepared using the Ficoll separation technique and purified with erythrocyte lysis. The cells were counted using Sysmex XN-3100 and then packaged and frozen according to a 50 µL volume containing 1.0 × 106 cells. TAC and MPA were extracted using MagnaBeads and quantified using an LC-MS/MS platform. The chromatography was run on a reversed-phase Waters Acquity UPLC BEH C18 column (1.7 µm, 50 mm × 2.1 mm) for gradient elution separation with a total run time of 4.5 min and a flow rate of 0.3 mL/min. Mobile phases A and B were water and methanol, respectively, each containing 2 mM ammonium acetate and 0.1% formic acid. Renal transplant recipients receiving TAC and MPA in combination were selected for clinical validation and divided into two groups: a stable group and an adverse outcome group. The concentrations were dynamically monitored at 5, 7, 14, and 21 days (D5, D7, D14, and D21) and 1, 2, 3, and 6 months (M1, M2, M3, and M6) after operation.Method performance validation was performed according to Food and Drug Administration guidelines, showing high specificity and sensitivity. The TAC and MPA calibration curves were linear (r2 = 0.9988 and r2 = 0.9990, respectively). Both intra-day and inter-day imprecision and inaccuracy were less than 15%. Matrix effects and recoveries were satisfactory. The TAC and MPA concentrations in 304 real PBMC samples from 47 renal transplant recipients were within the calibration curve range (0.12 to 16.40 ng/mL and 0.20 to 4.72 ng/mL, respectively). There was a weak correlation between PBMC-C0TAC and WB-C0TAC (p < 0.05), but no correlation was found for MPA. The level of immunosuppressive intra-patient variation (IPV) was higher in PBMC at 77.47% (55.06, 97.76%) than in WB at 34.61% (21.90, 49.85%). During the dynamic change in C0TAC, PBMC-C0TAC was in a fluctuating state, and no stable period was found. PBMC-C0TAC did not show a significant difference between the stable and adverse outcome group, but the level of the adverse outcome group was generally higher than that of the stable group.Compared with conventional therapeutic drug monitoring, the proposed rapid and sensitive method can provide more clinically reliable information on drug concentration at an active site, which has the potential to be applied to the clinical monitoring of intracellular immunosuppressive concentration in organ transplantation. However, the application of PBMC-C0TAC in adverse outcomes of renal transplant should be studied further." @default.
• W4386748890 created "2023-09-15" @default.
• W4386748890 creator A5002698291 @default.
• W4386748890 creator A5003769106 @default.
• W4386748890 creator A5017395632 @default.
• W4386748890 creator A5019603006 @default.
• W4386748890 creator A5022244759 @default.
• W4386748890 creator A5023378337 @default.
• W4386748890 creator A5029189683 @default.
• W4386748890 creator A5031029049 @default.
• W4386748890 creator A5045083143 @default.
• W4386748890 creator A5051759496 @default.
• W4386748890 creator A5072737937 @default.
• W4386748890 creator A5075377569 @default.
• W4386748890 creator A5083293268 @default.
• W4386748890 creator A5086342255 @default.
• W4386748890 date "2023-09-14" @default.
• W4386748890 modified "2023-10-17" @default.
• W4386748890 title "Dynamic Monitoring of Intracellular Tacrolimus and Mycophenolic Acid Therapy in Renal Transplant Recipients Using Magnetic Bead Extraction Combined with LC-MS/MS" @default.
• W4386748890 cites W1734239245 @default.
• W4386748890 cites W1891520818 @default.
• W4386748890 cites W1965390892 @default.
• W4386748890 cites W1977730145 @default.
• W4386748890 cites W1984831126 @default.
• W4386748890 cites W1994453026 @default.
• W4386748890 cites W2012512817 @default.
• W4386748890 cites W2035225463 @default.
• W4386748890 cites W2044038155 @default.
• W4386748890 cites W2057507419 @default.
• W4386748890 cites W2059188784 @default.
• W4386748890 cites W2069583058 @default.
• W4386748890 cites W2074604840 @default.
• W4386748890 cites W2081858766 @default.
• W4386748890 cites W2101399909 @default.
• W4386748890 cites W2104177803 @default.
• W4386748890 cites W2127001878 @default.
• W4386748890 cites W2153400906 @default.
• W4386748890 cites W2339616299 @default.
• W4386748890 cites W2487313992 @default.
• W4386748890 cites W2811299433 @default.
• W4386748890 cites W2886656503 @default.
• W4386748890 cites W2898261508 @default.
• W4386748890 cites W2941195870 @default.
• W4386748890 cites W2942232198 @default.
• W4386748890 cites W2942673049 @default.
• W4386748890 cites W2965313791 @default.
• W4386748890 cites W2991287203 @default.
• W4386748890 cites W3000349799 @default.
• W4386748890 cites W3092043401 @default.
• W4386748890 cites W3092645193 @default.
• W4386748890 cites W3126434098 @default.
• W4386748890 cites W4214826866 @default.
• W4386748890 doi "https://doi.org/10.3390/pharmaceutics15092318" @default.
• W4386748890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37765287" @default.
• W4386748890 hasPublicationYear "2023" @default.
• W4386748890 type Work @default.
• W4386748890 citedByCount "0" @default.
• W4386748890 crossrefType "journal-article" @default.
• W4386748890 hasAuthorship W4386748890A5002698291 @default.
• W4386748890 hasAuthorship W4386748890A5003769106 @default.
• W4386748890 hasAuthorship W4386748890A5017395632 @default.
• W4386748890 hasAuthorship W4386748890A5019603006 @default.
• W4386748890 hasAuthorship W4386748890A5022244759 @default.
• W4386748890 hasAuthorship W4386748890A5023378337 @default.
• W4386748890 hasAuthorship W4386748890A5029189683 @default.
• W4386748890 hasAuthorship W4386748890A5031029049 @default.
• W4386748890 hasAuthorship W4386748890A5045083143 @default.
• W4386748890 hasAuthorship W4386748890A5051759496 @default.
• W4386748890 hasAuthorship W4386748890A5072737937 @default.
• W4386748890 hasAuthorship W4386748890A5075377569 @default.
• W4386748890 hasAuthorship W4386748890A5083293268 @default.
• W4386748890 hasAuthorship W4386748890A5086342255 @default.
• W4386748890 hasBestOaLocation W43867488901 @default.
• W4386748890 hasConcept C112705442 @default.
• W4386748890 hasConcept C126322002 @default.
• W4386748890 hasConcept C137061746 @default.
• W4386748890 hasConcept C162356407 @default.
• W4386748890 hasConcept C179998833 @default.
• W4386748890 hasConcept C185592680 @default.
• W4386748890 hasConcept C202751555 @default.
• W4386748890 hasConcept C2777379063 @default.
• W4386748890 hasConcept C2778033501 @default.
• W4386748890 hasConcept C2780272996 @default.
• W4386748890 hasConcept C2909675724 @default.
• W4386748890 hasConcept C2911091166 @default.
• W4386748890 hasConcept C31827203 @default.
• W4386748890 hasConcept C43617362 @default.
• W4386748890 hasConcept C55493867 @default.
• W4386748890 hasConcept C64489805 @default.
• W4386748890 hasConcept C71043704 @default.
• W4386748890 hasConcept C71924100 @default.
• W4386748890 hasConcept C81426234 @default.
• W4386748890 hasConcept C98274493 @default.
• W4386748890 hasConceptScore W4386748890C112705442 @default.
• W4386748890 hasConceptScore W4386748890C126322002 @default.
• W4386748890 hasConceptScore W4386748890C137061746 @default.
• W4386748890 hasConceptScore W4386748890C162356407 @default.
• W4386748890 hasConceptScore W4386748890C179998833 @default.

• next